NCT01841333View on ClinicalTrials.gov

PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 29, 2013

Primary Completion Date

May 8, 2019

Study Completion Date

February 4, 2020

Conditions
Adult Acute Myeloid Leukemia in RemissionRecurrent Adult Acute Myeloid Leukemia
Interventions
DRUG

PF-04449913

100mg given orally

Trial Locations (2)

43210

Ohio State University, Columbus

80045

University of Colorado Cancer Center, Aurora

All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

lead

University of Colorado, Denver

OTHER

NCT01841333 - PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant | Biotech Hunter | Biotech Hunter